[go: up one dir, main page]

CL2013001779A1 - Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida; procedimiento de preparacion; y su uso para tratar el cancer. - Google Patents

Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida; procedimiento de preparacion; y su uso para tratar el cancer.

Info

Publication number
CL2013001779A1
CL2013001779A1 CL2013001779A CL2013001779A CL2013001779A1 CL 2013001779 A1 CL2013001779 A1 CL 2013001779A1 CL 2013001779 A CL2013001779 A CL 2013001779A CL 2013001779 A CL2013001779 A CL 2013001779A CL 2013001779 A1 CL2013001779 A1 CL 2013001779A1
Authority
CL
Chile
Prior art keywords
trioxo
pyrido
phenylamino
pyrimidin
iodo
Prior art date
Application number
CL2013001779A
Other languages
English (en)
Inventor
Douglas J Demarini
Ngocdiep T Le
Francisco Henriquez
Lihong Wang
Original Assignee
Glaxosmithkline Intellectual Property N 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001779(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property N 2 Ltd filed Critical Glaxosmithkline Intellectual Property N 2 Ltd
Publication of CL2013001779A1 publication Critical patent/CL2013001779A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2013001779A 2010-12-20 2013-06-18 Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida; procedimiento de preparacion; y su uso para tratar el cancer. CL2013001779A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
CL2013001779A1 true CL2013001779A1 (es) 2014-06-27

Family

ID=46314827

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001779A CL2013001779A1 (es) 2010-12-20 2013-06-18 Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida; procedimiento de preparacion; y su uso para tratar el cancer.

Country Status (38)

Country Link
US (5) US8580304B2 (es)
EP (4) EP4159204B1 (es)
JP (2) JP6126014B2 (es)
KR (1) KR101911109B1 (es)
CN (1) CN103998041B (es)
AR (2) AR084102A1 (es)
AU (1) AU2011349422B2 (es)
BR (1) BR112013015602B1 (es)
CA (1) CA2822701C (es)
CL (1) CL2013001779A1 (es)
CR (1) CR20130352A (es)
CY (1) CY1123376T1 (es)
DK (3) DK2654736T3 (es)
DO (1) DOP2013000138A (es)
EA (1) EA025198B1 (es)
ES (3) ES2820536T3 (es)
FI (2) FI4159205T3 (es)
HR (3) HRP20240563T1 (es)
HU (3) HUE050788T2 (es)
IL (1) IL226855A (es)
JO (1) JO3594B1 (es)
LT (3) LT2654736T (es)
MA (1) MA34883B1 (es)
MX (1) MX2013007073A (es)
MY (1) MY170501A (es)
NZ (1) NZ612157A (es)
PE (1) PE20140040A1 (es)
PH (1) PH12013501209A1 (es)
PL (3) PL4159204T3 (es)
PT (3) PT4159204T (es)
RS (2) RS65497B1 (es)
SG (1) SG191054A1 (es)
SI (3) SI4159205T1 (es)
TW (1) TWI505828B (es)
UA (1) UA113158C2 (es)
UY (1) UY33818A (es)
WO (1) WO2012088033A2 (es)
ZA (1) ZA201304189B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
RS59113B1 (sr) 2012-08-17 2019-09-30 Hoffmann La Roche Kombinovane terapije za melanom koje uključuju davanje kobimetiniba i vemurafiniba
JP6232443B2 (ja) * 2012-11-30 2017-11-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規な医薬組成物
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
CN116172869A (zh) * 2016-08-10 2023-05-30 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
TW201818936A (zh) 2016-11-25 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物醫藥組成物及其製備方法
FI3618875T3 (fi) 2017-05-02 2023-07-04 Novartis Ag Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
US12528772B2 (en) 2019-07-11 2026-01-20 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
PL2298768T3 (pl) 2004-06-11 2013-03-29 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
US20080145433A1 (en) * 2006-11-09 2008-06-19 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
UA99731C2 (ru) * 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP5719770B2 (ja) 2008-07-08 2015-05-20 ベータ・ファーマ・インコーポレイテッドＢｅｔａ Ｐｈａｒｍａ， Ｉｎｃ． 塩酸イコチニブ、合成物、結晶学的形態、併用薬及びその用途
EA201270453A1 (ru) 2009-09-23 2013-12-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинация
US20120322817A1 (en) 2009-09-23 2012-12-20 Melissa Dumble Combination
WO2011038380A2 (en) 2009-09-28 2011-03-31 Glaxosmithkline Llc Combination
EA020589B1 (ru) * 2009-10-16 2014-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Противораковая комбинация
US20120283279A1 (en) 2009-11-17 2012-11-08 Glaxosmithkline Llc Combination
WO2012027438A1 (en) 2010-08-26 2012-03-01 Glaxosmithkline Llc Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu

Also Published As

Publication number Publication date
HRP20240564T1 (hr) 2024-09-27
HRP20201409T1 (hr) 2020-11-27
RS65496B1 (sr) 2024-06-28
PT4159204T (pt) 2024-05-07
CA2822701A1 (en) 2012-06-28
ES2820536T3 (es) 2021-04-21
JP6126014B2 (ja) 2017-05-10
ES2982775T3 (es) 2024-10-17
WO2012088033A3 (en) 2014-03-13
FI4159205T3 (fi) 2024-04-23
JP2017137299A (ja) 2017-08-10
US20140037726A1 (en) 2014-02-06
AR084102A1 (es) 2013-04-24
US20140099365A1 (en) 2014-04-10
BR112013015602B1 (pt) 2022-03-03
UY33818A (es) 2012-07-31
MY170501A (en) 2019-08-08
US9271941B2 (en) 2016-03-01
PL4159205T3 (pl) 2024-06-24
HRP20240563T1 (hr) 2024-08-16
TWI505828B (zh) 2015-11-01
EP4159204A1 (en) 2023-04-05
LT2654736T (lt) 2020-09-25
JO3594B1 (ar) 2020-07-05
HUE066526T2 (hu) 2024-08-28
WO2012088033A2 (en) 2012-06-28
MX2013007073A (es) 2013-09-26
LT4159205T (lt) 2024-05-10
PT4159205T (pt) 2024-05-08
CA2822701C (en) 2018-10-23
EP4159205A1 (en) 2023-04-05
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
ZA201304189B (en) 2014-02-26
PH12013501209A1 (en) 2013-07-29
US20120183613A1 (en) 2012-07-19
LT4159204T (lt) 2024-05-10
EP3808343A1 (en) 2021-04-21
US20130266649A1 (en) 2013-10-10
EP2654736A4 (en) 2015-04-22
RS65497B1 (sr) 2024-06-28
HUE066525T2 (hu) 2024-08-28
TW201249441A (en) 2012-12-16
FI4159204T3 (fi) 2024-04-22
SG191054A1 (en) 2013-08-30
DK2654736T3 (da) 2020-09-14
PT2654736T (pt) 2020-09-24
JP2014510704A (ja) 2014-05-01
EP4159204B1 (en) 2024-02-14
SI4159204T1 (sl) 2024-06-28
DOP2013000138A (es) 2013-11-30
HUE050788T2 (hu) 2021-01-28
EA201390913A1 (ru) 2014-04-30
EP2654736A2 (en) 2013-10-30
PE20140040A1 (es) 2014-02-26
CN103998041B (zh) 2016-08-17
IL226855A (en) 2017-04-30
UA113158C2 (xx) 2016-12-26
EA025198B1 (ru) 2016-11-30
AU2011349422A1 (en) 2013-05-02
CN103998041A (zh) 2014-08-20
KR101911109B1 (ko) 2018-10-23
AU2011349422B2 (en) 2015-12-10
US9399021B2 (en) 2016-07-26
BR112013015602A2 (pt) 2017-02-21
KR20130130028A (ko) 2013-11-29
EP4159205B1 (en) 2024-02-14
CY1123376T1 (el) 2021-12-31
ES2985024T3 (es) 2024-11-04
MA34883B1 (fr) 2014-02-01
PL4159204T3 (pl) 2024-07-01
SI4159205T1 (sl) 2024-06-28
US8580304B2 (en) 2013-11-12
SI2654736T1 (sl) 2020-10-30
US9155706B2 (en) 2015-10-13
US20140154316A1 (en) 2014-06-05
CR20130352A (es) 2013-12-18
AR122185A2 (es) 2022-08-24
NZ612157A (en) 2015-05-29
PL2654736T3 (pl) 2020-12-14
DK4159205T3 (da) 2024-05-13

Similar Documents

Publication Publication Date Title
CL2013001779A1 (es) Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida; procedimiento de preparacion; y su uso para tratar el cancer.
CL2013001497A1 (es) Metodo para producir un preparado farmaceutico que contiene un inhibidor de la bomba de protones y un aine en forma de granulos esfericos; preparado farmaceutico; y su uso para el tratamiento del dolor e inflamacion en reumatismo, contusiones, esguinces y artrosis.
CR20150232A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
PT2521452E (pt) Tiazolo[5,4-d]pirimidinas e a sua utilização como agroquímicos
ZA201300100B (en) Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
IL236170A0 (en) 2,3-dihydro-h1-imidazo[a-1,2]pyrimidin-5-one and 1,2,3,4-tetrahydropyrimido[a-1,2]pyrimidin-6-one derivatives containing modified morpholine, their preparation and pharmaceutical use their
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
BR112013007022A2 (pt) uso de estearato de magnésio, formulação farmacêutica e inalador de pó seco
PL2448940T3 (pl) Pochodne 6,7,8,9-tetrahydro-pirymido{1,2-a} pirymidyn-4-onu, ich wytwarzanie i zastosowanie farmaceutyczne
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
UY35157A (es) Nueva composición farmacéutica conteniendo dimetilsulfóxido
NI201200157A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
LT2448939T (lt) 2,3-dihidro-1h-imidazo {1,2-a} pirimidin-5-ono dariniai, jų gamyba ir farmacinis panaudojimas
SI2588480T1 (sl) Derivati 3,4-dihidropirolo(1,2-a)pirazina-2,8(1H)-dikarboksamida, njihova priprava in terapevtska uporaba
CO6801756A2 (es) Derivas de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritimia
SG11201508653QA (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
CL2014003028A1 (es) Formulacion parenteral de clorhidrato de esmolol; metodo de produccion; kit farmaceutico; uso para tratar descompensacion cardiaca y/o renal y/o hipernatremia y/o acidosis hipercloramica.
FR2969612B1 (fr) Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
CO6781490A2 (es) Nueva composición farmacéutica